{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:22:38Z","timestamp":1790713358483,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13014-018-1185-9","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T06:51:59Z","timestamp":1543215119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5\u2009years of follow-up"],"prefix":"10.1186","volume":"13","author":[{"given":"Marta","family":"Scorsetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Comito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Iftode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Di Brina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierina","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mancosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Reggiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Fogliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tomatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Torzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-898X","authenticated-orcid":false,"given":"Luca","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","volume":"64","author":"CE De Santis","year":"2014","unstructured":"De Santis CE, Lin CC, Mariotto AB, Siegel RL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252\u201371.","journal-title":"CA Cancer J Clin"},{"key":"1185_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378\u201382.3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1245\/ASO.2006.05.039","volume":"13","author":"AC Wei","year":"2006","unstructured":"Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668\u201376.12.","journal-title":"Ann Surg Oncol"},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309\u201318 13.","journal-title":"Ann Surg"},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","volume":"25","author":"JS Tomlinson","year":"2007","unstructured":"Tomlinson JS, Jarnagin WR, Dematteo RP, et al. Actual 10-yearsurvival after resection of 514 colorectal liver metastases defines cure. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:4575\u201380 14.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1245\/s10434-008-9935-9","volume":"15","author":"L Vigano","year":"2008","unstructured":"Vigano L, Ferrero A, Lo Tesoriere R, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008;15:2458\u201364.","journal-title":"Ann Surg Oncol"},{"key":"1185_CR7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s00330-008-1258-5","volume":"19","author":"AR Gillams","year":"2009","unstructured":"Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19:1206\u201313 22.","journal-title":"Eur Radiol"},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/SLA.0b013e318155a7b6","volume":"246","author":"AE Siperstein","year":"2007","unstructured":"Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases,10-year experience. Ann Surg. 2007;246:559\u201367.","journal-title":"Ann Surg"},{"key":"1185_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1200\/JCO.2001.19.1.164","volume":"19","author":"KK Herfarth","year":"2001","unstructured":"Herfarth KK, Debus J, Wannenmacher M. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I\/II trial. J Clin Oncol. 2001;19:164\u201370 35.","journal-title":"J Clin Oncol"},{"key":"1185_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","volume":"27","author":"MT Lee","year":"2009","unstructured":"Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585\u201391 36.","journal-title":"J Clin Oncol"},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","volume":"78","author":"KA Goodman","year":"2010","unstructured":"Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486\u201393 37.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","volume":"27","author":"KE Rusthoven","year":"2009","unstructured":"Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572\u20138 38.","journal-title":"J Clin Oncol"},{"key":"1185_CR13","first-page":"3381","volume":"29","author":"G Ambrosino","year":"2009","unstructured":"Ambrosino G, Polistina F, Costantin G, et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009;29:3381\u20134 39.","journal-title":"Anticancer Res"},{"key":"1185_CR14","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ijrobp.2007.08.058","volume":"70","author":"A Mendez Romero","year":"2008","unstructured":"Mendez Romero A, Wunderink W, van Os RM, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys. 2008;70:1447\u201352 40.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1185_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/02841860600904854","volume":"45","author":"M Hoyer","year":"2006","unstructured":"Hoyer M, Roed H, Traberg HA, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823\u201330.","journal-title":"Acta Oncol"},{"key":"1185_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijrobp.2012.12.021","volume":"86","author":"M Scorsetti","year":"2013","unstructured":"Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86:336\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","volume":"141","author":"M Scorsetti","year":"2015","unstructured":"Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, CLerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Concol. 2015;141:543\u201353.","journal-title":"J Cancer Res Clin Concol"},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1002\/cncr.25997","volume":"117","author":"DT Chang","year":"2011","unstructured":"Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases. A pooled analysis. Cancer. 2011;117:4060\u20139.46.","journal-title":"Cancer"},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.radonc.2014.12.003","volume":"114","author":"MM Fode","year":"2015","unstructured":"Fode MM, H\u00f8yer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015;114:155\u201360.","journal-title":"Radiother Oncol"},{"key":"1185_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/1471-2407-14-619","volume":"14","author":"T Comito","year":"2014","unstructured":"Comito T, Cozzi L, Clerici E, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14:619.","journal-title":"BMC Cancer"},{"issue":"10","key":"1185_CR21","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1200\/JCO.2008.21.7299","volume":"27","author":"Edgar Ben-Josef","year":"2009","unstructured":"Ben-Josef E, Lawrence TS. Using a bigger hammer: the role of stereotactic body radiotherapy in the management of oligometastases. J Clin Oncol. 2009;27:1537\u20139.","journal-title":"Journal of Clinical Oncology"},{"key":"1185_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijrobp.2008.03.062","volume":"73","author":"R McCammon","year":"2009","unstructured":"McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73:112\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/jso.23058","volume":"106","author":"SH Bae","year":"2012","unstructured":"Bae SH, Kim MS, Cho CK, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol. 2012;106:138\u201343.","journal-title":"J Surg Oncol"},{"key":"1185_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"E Eisenhauer","year":"2009","unstructured":"Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1185_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1477-2574.2012.00557.x","volume":"15","author":"RB Adams","year":"2013","unstructured":"Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB. 2013;15:91\u2013103.","journal-title":"HPB"},{"key":"1185_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1245\/s10434-015-4579-z","volume":"23","author":"JJ Meyer","year":"2016","unstructured":"Meyer JJ, Foster RD, Lev-Cohain N, et al. A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases. Ann Surg Oncol. 2016;23:218\u201324.","journal-title":"Ann Surg Oncol"},{"key":"1185_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2016.10.024","volume":"122","author":"DA Toesca","year":"2017","unstructured":"Toesca DA, Osmundson EC, Eyben RV, et al. Central liver toxicity after SBRT: an expanded analysis and predictive nomogram. Radiother Oncol. 2017;122:130\u20136.","journal-title":"Radiother Oncol"},{"key":"1185_CR28","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol"},{"key":"1185_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","volume":"141","author":"M Scorsetti","year":"2015","unstructured":"Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141:1301\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1185_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ijrobp.2017.04.010","volume":"99","author":"A McPartlin","year":"2017","unstructured":"McPartlin A, Swaminath A, Wang R, et al. Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases. Int J Radiat Oncol Biol Phys. 2017;99:388\u201395.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1185_CR31","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","volume":"99","author":"JH Joo","year":"2017","unstructured":"Joo JH, Park JH, Kim JC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99:876\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1185_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","volume":"123","author":"RJ Klement","year":"2017","unstructured":"Klement RJ, Guckenberger M, Alheid H, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123:227\u201333.","journal-title":"Radiother Oncol"},{"key":"1185_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.radonc.2017.03.014","volume":"123","author":"RJ Klement","year":"2017","unstructured":"Klement RJ. Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. Radiother Oncol. 2017;123:218\u201326.","journal-title":"Radiother Oncol"},{"key":"1185_CR34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","volume":"95","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95:1399\u2013404.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1185_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000343863","volume":"3","author":"N Oishi","year":"2014","unstructured":"Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer. 2014;3:71\u201384.","journal-title":"Liver Cancer"},{"key":"1185_CR36","doi-asserted-by":"publisher","first-page":"309e18","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309e18.","journal-title":"Ann Surg"},{"key":"1185_CR37","doi-asserted-by":"publisher","first-page":"234e42","DOI":"10.1097\/SLA.0b013e318223c609","volume":"254","author":"M Dhir","year":"2011","unstructured":"Dhir M, Lyden ER, Wang A, Smith LM, Ullrich F, Are C. Influence of margins on overall survival after hepatic resection for colorectal metastasis: a meta-analysis. Ann Surg. 2011;254:234e42.","journal-title":"Ann Surg"},{"key":"1185_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","volume":"371","author":"B Nordlinger","year":"2008","unstructured":"Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomized controlled trial. Lancet. 2008;371:1007\u201316.","journal-title":"Lancet"},{"key":"1185_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.breast.2016.09.011","volume":"30","author":"K Fairhurst","year":"2016","unstructured":"Fairhurst K, Leopardi L, Satyadas T, Maddern G. The safety and effectiveness of liver resection for breast cancer liver metastases: a systematic review. Breast. 2016;30:175\u201384.","journal-title":"Breast"},{"key":"1185_CR40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/01.sla.0000246847.02058.1b","volume":"244","author":"R Adam","year":"2006","unstructured":"Adam R, Chiche L, Aloia T, et al. Hepatic resection for non-colorectal non-endocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg. 2006;244:524\u201335.","journal-title":"Ann Surg"},{"key":"1185_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.prro.2015.10.011","volume":"6","author":"B Goodman","year":"2016","unstructured":"Goodman B, Mannina E, Althouse S, Maluccio M, C\u00e1rdenes H. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6:86\u201395.","journal-title":"Pract Radiat Oncol"},{"key":"1185_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.rpor.2016.10.003","volume":"22","author":"A M\u00e9ndez Romero","year":"2017","unstructured":"M\u00e9ndez Romero A, Keskin-Cambay F, van Os RM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017;22:126\u201331.","journal-title":"Rep Pract Oncol Radiother"},{"key":"1185_CR43","doi-asserted-by":"publisher","first-page":"20180058","DOI":"10.1259\/bjr.20180058","volume":"91","author":"R Mazzola","year":"2018","unstructured":"Mazzola R, Fersino S, Alongi P, Di Paola F, Gregucci F, Aiello D, et al. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET\/CT. Br J Radiol. 2018;91:20180058.","journal-title":"Br J Radiol"},{"key":"1185_CR44","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.2147\/OTT.S165878","volume":"11","author":"P Ihnat","year":"2018","unstructured":"Ihnat P, Skacelikova E, Tesar M, Penka I. Stereotactic body radiotherapy using the CyberKnife system in the treatment of patients with liver metastases: state of the art. Onco Targets. 2018;11:4685\u201391.","journal-title":"Onco Targets"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-018-1185-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T19:17:31Z","timestamp":1574709451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-018-1185-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1186\/s13014-018-1185-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Humanitas Ethical Committee approved the study. Informed consent to participate in the treatment was obtained from each patient at admission.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L. Cozzi acts as Scientific Advisor to Varian Medical Systems and is Clinical Research Scientist at Humanitas Cancer Center. All other co-authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"234"}}